The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
over 4 years ago
P2 data • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)
The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
almost 5 years ago
P2 data • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)
The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
almost 5 years ago
P2 data • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)